

Curriculum vitae Valeria Barresi, MD, PhD

Professional summary

Associate Professor of Anatomic Pathology and PhD in Clinical, Experimental Applied Oncology and Translational Research on Tumors.

Author of 240 publications in international, peer-reviewed journals with impact factor. 126 of these were published as the first/last author.

Accredited as Full Professor of Pathology by the Italian Ministry for University and Research in April 2020.

Reviewer of scientific projects for La Caixa Foundation, Dutch Cancer Society (The Netherlands) and Latvian Council of Science (Latvia)

Member of the European Pituitary Pathology Group.

Member of the Scientific Committee of the Brain Research Foundation Onlus in Verona, Italy.

Chair of the Italian Group of Neuropathology in the Italian Society of Anatomic Pathology and Cytopathology (SIAPEC).

Main research interests: molecular classification and prognostic factors in central nervous system tumors; epithelial mesenchymal transition in colorectal cancer

<https://www.scopus.com/authid/detail.uri?authorId=14055363500>

<https://orcid.org/0000-0001-7086-1920>

Personal details

Place and date of birth: Messina, March, the 4th 1977

Nationality: italian

e-mail: valeria.barresi@univr.it

Foreign languages

English: B2 (Trinity College, Level 9 with distinction)

Spanish: fluent

Accreditations

Italian Scientific Accreditation for Full Professor of Anatomic Pathology

Education

2010: PhD in Clinical, Experimental Applied Oncology and Translational Research on Tumors, University of Messina, Italy

2006: Specialist in Anatomic Pathology, University of Messina, Italy (50/50 and laude)

2001: Degree in Medicine and Surgery, University of Messina, Italy (110/110 and laude)

Positions

September 2023: Responsible of the Unit of Neuropathology, Azienda Ospedaliera Universitaria, Verona, Italy

October 2018-now: Associate Professor of Anatomic Pathology, University of Verona, Italy

Pathologist at Azienda Ospedaliera Universitaria Verona, Italy, with expertise in neuropathology

May 2018- October 2018: Associate Professor of Anatomic Pathology, University of Messina, Italy

Pathologist with expertise in Neuropathology, at Policlinico Universitario G. Martino, Italy

March 2008- May 2018: Assistant Professor of Anatomic Pathology, University of Messina, Italy

Pathologist with expertise in Neuropathology, at Policlinico Universitario G. Martino, Italy

Frequency of international institutions

June 2017: Unit of Neuropathology, University of Manchester, UK (prof. F. Roncaroli)

June - July 2016: Division of Neuropathology, Johns Hopkins University, Baltimore, MD, USA (prof. F.J. Rodriguez, prof. C. Eberhart, prof. P. Burger)

Editorial Board international peer-reviewed journals

- *Cancers* (Guest Editor), since 2021, IF: 5.2
- *Biomedicines*, since 2020, IF: 4.7
- *Frontiers in Oncology*, since 2019, IF: 5.73
- *Glioma*, since 2017
- *Diagnostic Pathology*, since 2015, IF: 3.196
- *Disease Markers*, since 2014, IF: 3.464
- *Biomed Research International*, 2013-2022, IF: 2.276
- *Pathologica*, (2015-2018)

Reviewer of research projects

- Latvian Council of Science, Latvia, 2024: evaluation of 1 research project
- La Caixa Foundation, Spain, 2024: evaluation of 10 research projects
- La Caixa Foundation, Spain, 2023: evaluation of 5 research projects
- La Caixa Foundation, Spain, 2022: evaluation of 5 research projects
- La Caixa Foundation, Spain, 2021: evaluation of 11 research projects
- Italian Ministry of Health, 2020: evaluation of 1 research project
- La Caixa Foundation, Spain, 2021: evaluation of 3 research projects
- Italian Ministry of Health, 2016: evaluation of 14 research projects
- Dutch Cancer Society, 2016: evaluation of 1 research project on tumor budding in colorectal cancer
- Italian Ministry of University and Research 2013: evaluation of 3 research projects
- Italian Ministry of University and Research, evaluator of research quality, 2011-2014
- Italian Ministry of University and Research, evaluator of research quality, 2004-2010

International evaluator for the accreditation of degrees and master courses

- Agencia de Calidad y Prospectiva Universitaria de Aragon, May 2021: international evaluator for the renewal of the accreditation of the degrees in Nursery, Fisiotherapy and Occupational Therapy, University of Zaragoza, Spain
- Agencia de Calidad y Prospectiva Universitaria de Aragon, March 2020: international evaluator for the renewal of the accreditation of the master Atención Farmacéutica y Farmacoterapia por la Universidad San Jorge", University of Zaragoza, Spain
- Agencia de Calidad y Prospectiva Universitaria de Aragon, November 2016: Accreditation of Degree in Medicine and Surgery, University of Zaragoza, Spain

Reviewer for scientific journals

Reviewer for 56 international peer-reviewed journals with impact factor and total 202 reviewed papers

Activity pathology outlines website

Member of the Editorial Board for Neuropathology section

Authors of the following Chapters

- **Anaplastic meningioma** (Barresi V. Anaplastic meningioma. PathologyOutlines.com website. <https://www.pathologyoutlines.com/topic/cnstumoranaplasticmeningioma.html>)
- **Chordoid meningioma** (Barresi V. Chordoid meningioma. PathologyOutlines.com website. <https://www.pathologyoutlines.com/topic/cnstumorchordoidmeningioma.html>)
- **Schwannoma, CNS** (Barresi V. Schwannoma. PathologyOutlines.com website. <https://www.pathologyoutlines.com/topic/cnstumorschwannoma.html>)
- **Cerebellar liponeurocytoma** (Mulone D, Barresi V. Cerebellar liponeurocytoma. PathologyOutlines.com website. <https://www.pathologyoutlines.com/topic/cnstumorcerebellarliponeurocytoma.html>).

Research Grants

Principal investigator

2022: PRIN (Research project of National Interest), “Radiological, molecular and histological study of IDH wild-type glioblastoma characterized by RB1 alteration: towards the identification of a new variant potentially responsive to immunotherapy”, (Euros 256469)

Co-principal investigator

2022: PNRR Proof of Concept, “Theranostics in gastric cancer through immunotargeting of the CSPG4 cell surface proteoglycan” (codice PNRR-POC2022-12376831 (euros 810790)

2018: Call “Research & Mobility”, University of Messina, Italy, “Molecular typing of glioblastoma in patients younger than 50 years. Identification of potential prognostic and predictive factors and targets for novel therapy” (Euros 70357)

Teaching

Master degrees

Nov 2018-now: Medicine and Surgery, University of Verona, Italy

Mar 2008-Oct 2018: Medicine and Surgery, University of Verona, Italy

Bachelor degrees

Nov 2021- now: Orthopedics technician, University of Verona, Italy

Nov 2020- Oct 2021: Laboratory assistant, University of Verona, Italy

Nov 2019-now: Obstetrics, University of Verona, Italy

Nov 2010- Oct 2015: Physiotherapy, University of Messina, Italy

Medical Specialization schools

Nov 2022- now: Neurosurgery, University of Verona, Italy

Oct 2018- now: Anatomic Pathology, University of Verona, Italy

Nov 2020- now: Orthopedics; Oral Surgery; Emergency Medicine; Allergology and clinical Immunology; Obstetrics and Gynecology

Nov 2009-Oct 2018: Anatomic Pathology, University of Messina, Italy

Nov 2009-Oct 2018: Neurosurgery; Neurophysiopathology; Pediatric Neuropsychiatry; Neurology

PhD Courses

Apr 2019- now: PhD in Inflammation, Immunity and Cancer, University of Verona, Italy

2013-2018: Biotechnologies in Medicine and Surgery, University of Messina, Italy

2012-2013: Translational Research in Neurosciences and Oncology, University of Messina, Italy

Scientific papers

240 papers on peer-reviewed international journals with impact factor.

Papers are mainly focused on central nervous system tumors and on colorectal cancer

Authorship	N. of papers	Corresponding author
First author	101	96
Second author	31	2
Third author	23	-
Last author	25	22
Collaborator	60	-
Total	240	120

Bibliometric indices	Scopus	Google scholar
H-index	32	41
Citations	3855	5508

LIST OF PUBLICATIONS

First author

1. **Barresi V**, Cardoni A, Miele E, Pedace L, Masotto B, Nardini C, Barresi S, Rossi S. CNS tumor with CREBBP::BCORL1 Fusion and pathogenic mutations in BCOR and CREBBP: expanding the spectrum of BCOR-altered tumors. *Acta Neuropathol Commun.* 2024 Jan 12;12(1):8.
2. **Barresi V**, Ammendola S, Simbolo M, Pedron S, Caffo M, Scarpa A. Atypical meningiomas with an immunohistochemical profile consistent with hypermetabolic or proliferative molecular groups show high mitotic index, chromosomal instability, and higher recurrence risk. *Virchows Arch. Virchows Arch.* 2023 Jul;483(1):97-104 (corresponding author)
3. **Barresi V**, Gianni F, Marucci G. Newly recognised Tumour Types in Glioneuronal tumours according to the 5th edition of the CNS WHO Classification. *Pathologica.* 2022 Dec;114(6):447-454.
4. **Barresi V**, Simbolo M, Ciaparrone C, Pedron S, Mafficini A, Scarpa A. pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells. *Histopathology.* 2022;81(5):661-669 (corresponding author)
5. **Barresi V**, Lawlor RT, Mafficini A, Gilioli E, Scarpa A. Metastatic grade 1 meningioma lacking genetic abnormalities commonly associated with bad prognosis. *Pathol Res Pract.* 2022 Oct;238:154089 (corresponding author)
6. **Barresi V**, Mafficini A, Calicchia M, Piredda ML, Musumeci A, Ghimenton C, Scarpa A. Recurrent oligodendroglioma with changed 1p/19q status. *Neuropathology.* 2022 Apr;42(2):160-166. (corresponding author)
7. **Barresi V**, Simbolo M, Mafficini A, Martini M, Calicchia M, Piredda ML, Ciaparrone C, Bonizzato G, Ammendola S, Caffo M, Pinna G, Sala F, Lawlor RT, Ghimenton C, Scarpa A. IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation. *Acta Neuropathol Commun.* 2021 Dec 24;9(1):200. doi: 10.1186/s40478-021-01304-5. PMID: 34952640; PMCID: PMC8709962 corresponding author)
8. **Barresi V**. Colorectal Cancer: From Pathophysiology to Novel Therapeutic Approaches. *Biomedicines.* 2021 Dec 8;9(12):1858. doi: 10.3390/biomedicines9121858. PMID: 34944674; PMCID: PMC8698346 (corresponding author)
9. **Barresi V**, Simbolo M, Fioravanzo A, Piredda ML, Caffo M, Ghimenton C, Pinna G, Longhi M, Nicolato A, Scarpa A. Molecular Profiling of 22 Primary Atypical Meningiomas Shows the Prognostic Significance of 18q Heterozygous Loss and CDKN2A/B Homozygous Deletion on Recurrence-Free Survival. *Cancers (Basel).* 2021 Feb 21;13(4):903. doi: 10.3390/cancers13040903. (corresponding author)
10. **Barresi V**, Simbolo M, Gessi M, Rossi S, Caffo M, Eccher A, Angileri FF, Cannavò S, Brunelli M, Scarpa A. Clinical-Pathological, Immunohistochemical, and Genetic Characterization of a Series of Posterior Pituitary Tumors. *J Neuropathol Exp Neurol.* 2021;80:45-51 (corresponding author).
11. **Barresi V**, Pedrazzani C. Colorectal signet ring cell carcinoma: advancing research in a rare cancer. *Future Oncol.* 2020;16(17):1161-1163. doi:10.2217/fon-2020-0242 (corresponding author)
12. **Barresi V**, Caffo M. Nuclear H3 K27me3 is retained in both components of dual genotype oligoastrocytoma 2020 Aug;40(4):407-409 (corresponding author)
13. **Barresi V**, Simbolo M, Mafficini A, Piredda ML, Caffo M, Cardali SM, Germanò A, Cingarlini S, Ghimenton C, Scarpa A. Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment. *Cancers (Basel).* 2019 Aug 30;11(9) (corresponding author)
14. **Barresi V**, Eccher A, Simbolo M, Cappellini R, Ricciardi GK, Calabria F, Cancedda M, Mazzarotto R, Bonetti B, Pinna G, Sala F, Ghimenton C, Scarpa A. Diffuse gliomas in patients aged 55 years or over: a suggestion for IDH mutation testing. *Neuropathology.* 2020;40: 68-74 (corresponding author)

15. **Barresi V**, Fioravanzo A, Pecori S, Tomezzoli A, Reggiani Bonetti L. The histopathologic report of surgically resected colorectal liver metastases: what is clinically relevant? *Pathol Res Pract* 2019 Sep;215(9):152547 (Corresponding author)
16. **Barresi V**, Conti A, Tomasello F. Commentary: Radiological Characteristics and Natural History of Adult IDH-Wild-Type Astrocytomas With TERT Promoter Mutations. *Neurosurgery*. 2019 85(3):E459-E460 doi: 10.1093/neuros/nyy618
17. **Barresi V**, Lioni S, La Rocca L, Caliri S, Caffo M. High p-mTOR expression is associated with recurrence and shorter disease-free survival in atypical meningiomas . *Neuropathology*; 39:22-29 (corresponding author)
18. **Barresi V**, Nunnari CM, Lioni S. Immunohistochemical stains to detect residual tumor in cystectomy specimens taken shortly after transurethral resection of bladder tumors. *Ann Diagn Pathol*. 2019; 40:176-179 (corresponding author; letter)
19. **Barresi V**. HOXB13 is not expressed in pleomorphic giant cell carcinoma of the bladder. *Virchows Arch*. 2018 473(2):259-260 (corresponding author; letter)
20. Reggiani Bonetti L, **Barresi V**, Maiorana A, Manfredini S, Caprera C, Bettelli S. Clinical impact and prognostic role of KRAS/BRAF/PIK3CA mutations in stage I colorectal cancer. *Dis Markers* 2018; 2018:2959801 (*co-primo autore; corresponding author)
21. **Barresi V**, Lioni S, Caliri S, Caffo M. Histopathological features to define atypical meningioma: what does really matter for prognosis? *Brain Tumor Pathol* 2018; 35(3):168-180 (corresponding author)
22. **Barresi V**. Conflicting IDH1/IDH2, ATRX, and 1p/19q results in diffuse gliomas: a commentary. *Hum Pathol* 2018 Dec;82:297-298 (corresponding author; letter).
23. **Barresi V**, Lioni S, Reggiani Bonetti L. Poorly differentiated clusters in colorectal liver metastases: Prognostic significance in synchronous and metachronous metastases. *J Surg Oncol* 2018 Jun;117(8):1856-1857 (corresponding author; letter)
24. **Barresi V**, Lioni S, Esposito F, Raso A, Cannavò S, Angileri FF. Pituitary Atypical Teratoid Rhabdoid Tumor in a patient with prolactinoma: a unique description. *Neuropathology* 2018 Jun;38(3):260-267 (corresponding author)
25. **Barresi V**, Reggiani Bonetti L, Ieni A, Caruso RA, Tuccari G. Poorly Differentiated Clusters: Clinical Impact in Colorectal Cancer. *Clin Colorectal Cancer*. 2017 Mar;16(1):9-15. (corresponding author)
26. **Barresi V**, Lioni S, Valori L, Gallina G, Rossi S. Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon oligoastrocytoma As a Distinct Entity? *JNEN*. 2017; 76: 342-346 (corresponding author)
27. **Barresi V**, Caffo M. Rhabdoid Meningioma: Grading and Prognostic Significance of this Uncommon variant. *JNEN* 2017; 76: 414-416 (corresponding author; letter)
28. **Barresi V**, Barns D, Grundmeyer R, Rodriguez FJ. Cystic endosalpingiosis of lumbar nerve root: a unique presentation. *Clin Neuropathol*. 2017; 36:108-113 (corresponding author)
29. **Barresi V**, Lioni S, Messina E, Esposito F, Angileri FF, Cannavò S. A 53-year-old woman with Cushing's disease and a pituitary tumor. *Neuropathology*. 2017;37:86-90 (corresponding author)
30. Reggiani Bonetti L, **Barresi V**, Bettelli S, Caprera C, Manfredini S, Maiorana A. Analysis of KRAS, NRAS, PIK3CA and BRAF mutational profile in poorly differentiated clusters (PDC) of KRAS mutated colon cancer. *Hum Pathol*. 2017; 62:91-98 (*co-primo autore; corresponding author)
31. **Barresi V**, Branca G, Raso A, Mascelli S, Caffo M, Tuccari G. Atypical teratoid rhabdoid tumor involving the nasal cavities and anterior skull base. *Neuropathology*. 2016; 36:286-289. (corresponding author)
32. **Barresi V**, Reggiani Bonetti L, Ieni A, Branca G, Tuccari G. Histologic prognostic markers in stage IIA colorectal cancer: a comparative study. *Scand J Gastroenterol*. 2016 Mar;51(3):314-20. (corresponding author)
33. **Barresi V**, Caffo M, Licata L, Angileri FF. A 59-year old female with a retrosellar mass. *Brain Pathol* 2016; 26: 557-558 (IF: 6.508; corresponding author)
34. **Barresi V**, Ieni A, Cardia R, Licata L, Vitarelli E, Reggiani Bonetti L, Tuccari G. HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors. *APMIS*. 2016;124:188-193. (corresponding author)
35. **Barresi V**, Ieni A, Reggiani Bonetti L, Tuccari G. HOXB13 expression in metastatic prostate cancer. *Virchows Arch*. 2016; 469:119-120 (corresponding author; letter)
36. **Barresi V**, Reggiani Bonetti L, Branca G, Vitarelli E, Ieni A, Tuccari G. Prognostic value of the density of Wilms tumour protein 1 (WT-1) positive microvessels in stage IIA colorectal cancer. *Int J Clin Exp Pathol* 2016; 9:3115-3124. (corresponding author)
37. **Barresi V**, Caffo M, Tuccari G. Classification of human meningiomas: lights, shadows, and future perspectives. *J Neurosci Res*. 2016; 94: 1604-1612 (corresponding author)

38. **Barresi V**, Reggiani Bonetti L, Domati F, Baron L. Prognostic relevance of histopathological features in signet ring cell carcinoma of the colorectum. *Virchows Arch* 2016;469:267-275 (corresponding author)
39. **Barresi V**, Reggiani Bonetti L, Ieni A, Domati F, Tuccari G. Prognostic significance of grading based on the counting of poorly differentiated clusters in colorectal mucinous adenocarcinoma. *Hum Pathol*. 2015;46(11):1722-9. (corresponding author)
40. **Barresi V**, Mondello S, Branca G, Rajan TS, Vitarelli E, Tuccari G. p-CREB expression in human gliomas: potential use in the differential diagnosis between astrocytoma and oligodendroglioma. *Hum Pathol*. 2015;46(2):231-8 (corresponding author)
41. **Barresi V**, Branca G, Caffo M, Tuccari G. p-CREB expression in human meningiomas: correlation with angiogenesis and recurrence risk. *J Neurooncol*. 2015 Mar;122(1):87-95. (corresponding author)
42. **Barresi V**, Caffo M, Branca G, Vitarelli E, Tuccari G. The density of microvessels positive for Wilms' tumour-1 protein (WT-1) is an independent predictor of recurrence risk in meningiomas. *Brain Tumor Pathol*. 2015 Jul;32(3):202-9. (corresponding author)
43. **Barresi V**, Bonetti LR. Correlation between microsatellite instability status and grading assessed by the counting of poorly differentiated clusters in colorectal cancer. *Hum Pathol*. 2015 Jul;46(7):1063. (corresponding author; letter)
44. **Barresi V**, Branca G, Ieni A, Rigoli L, Tuccari G, Caruso RA. Phagocytosis (cannibalism) of apoptotic neutrophils by tumor cells in gastric micropapillary carcinomas. *World J Gastroenterol*. 2015 May 14;21(18):5548-54.
45. **Barresi V**, Reggiani Bonetti L, Ieni A, Caruso RA, Tuccari G. Histological grading in colorectal cancer: new insights and perspectives. *Histol Histopathol*. 2015 Sep;30(9):1059-67. (corresponding author)
46. **Barresi V**, Bonetti LR, Bettelli S. KRAS, NRAS, BRAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: observational analysis of 175 cases. *Pathology*. 2015 Oct;47(6):551-6. (corresponding author)
47. **Barresi V**, Reggiani Bonetti L, Ieni A, Branca G, Baron L, Tuccari G. Histological grading based on the count of poorly differentiated clusters in pre-operative biopsy predicts nodal involvement and pTNM stage in colorectal cancer patients. *Human Pathol* 2014; 45: 268-275 (corresponding author)
48. **Barresi V**, Branca G, Ieni A, Reggiani Bonetti L, Baron L, Mondello S, Tuccari G. Poorly differentiated clusters (PDCs) as a novel histological predictor of nodal metastases in pT1 colorectal cancer. *Virchows Arch*. 2014;464:655-662 (corresponding author)
49. **Barresi V**, Ieni A, Branca G, Tuccari G Brachyury: A Diagnostic Marker for the Differential Diagnosis of Chordoma and Hemangioblastoma versus Neoplastic Histological Mimickers. *Dis Markers* 2014:514753. (corresponding author)
50. **Barresi V**, Branca G, Caffo M, Caltabiano R, Ieni A, Vitarelli E, Lanzafame S, Tuccari G. Immunorexpression of endoglin and smooth muscle actin in the vessels of brain metastases. Is there a rational for anti-angiogenic therapy? *Int J Mol Sci*. 2014 Apr 2;15(4):5663-79. (corresponding author)
51. **Barresi V**, Branca G, Vitarelli E, Tuccari G. Micropapillary pattern and poorly differentiated clusters represent the same biological phenomenon in colorectal cancer: a proposal for a change in terminology. *Am J Clin Pathol*. 2014;142(3):375-83. (corresponding author)
52. **Barresi V**, Tuccari G. Colorectal carcinoma grading by quantifying poorly differentiated clusters: is it feasible on endoscopic biopsies? *Am J Surg Pathol* 2013; 37:943-945. (corresponding author; letter)
53. **Barresi V**, Giuffrè G, Caruso RA, Tuccari G. HER2 Status in Rarer Histologic Types of Gastric Adenocarcinomas. *Arch Pathol Lab Med*. 2013 Jun;137(6):741 (letter)
54. **Barresi V**, Branca G, Granata F, Alafaci C, Caffo M, Tuccari G. Embolized meningiomas: risk of overgrading and neo-angiogenesis. *J Neurooncol*. 2013; 113: 207-219. (corresponding author)
55. **Barresi V**, Reggiani Bonetti L, Vitarelli E, Di Gregorio C, Ponz de Leon M, Barresi G. Immunohistochemical assessment of lymphovascular invasion in stage I colorectal carcinoma: prognostic relevance and correlation with nodal micrometastases. *Am J Surg Pathol* 2012;36:66-72 (corresponding author)
56. **Barresi V**, Branca G, Vitarelli E, Antonelli M, Giangaspero F, Barresi G. Expression of brachyury in hemangioblastoma: potential use in the differential Diagnosis. *Am J Surg Pathol* 2012; 36:1052-1057. (corresponding author)
57. **Barresi V**, Reggiani Bonetti L, Branca G, Di Gregorio C, Ponz de Leon M, Tuccari G. Colorectal carcinoma grading by quantifying poorly differentiated cell clusters is more reproducible and provides more robust prognostic information than conventional grading. *Virchows Arch* 2012; 461:621-628. (corresponding author)
58. **Barresi V**, Ieni A, Tuccari G, Barresi G. Neutrophil gelatinase-associate lipocalin (NGAL) immunohistochemical expression in follicular-cell derived thyroid tumors: a novel diagnostic tool? *Histol Histopathol* 2012; 27:329-336. (corresponding author)

59. **Barresi V**, Caffo M, Alafaci C, Granata F, Tuccari G. Intradural chordoma of the Meckel's cave: a challenging differential diagnosis. *Neuropathology* 2012; 32:577-582 (corresponding author)
60. **Barresi V**, Vitarelli E, Reggiani Bonetti L, Tuccari G, Barresi G. Diagnostic value of neutrophil gelatinase-associated lipocalin (NGAL) immunoexpression in follicular-patterned lesions of the thyroid gland. *Virchows Arch.* 2012;460:319-325. (corresponding author)
61. **Barresi V**, Alafaci C, Caffo M, Barresi G, Tuccari G. Clinico-pathological characteristics, hormone receptor status and matrix metallo-proteinase-9 (MMP-9) immunohistochemical expression in spinal meningiomas. *Pathology Research and Practice* 2012; 208: 350-355. (corresponding author)
62. **Barresi V**, Caffo M, Branca G, Caltabiano R, Tuccari G. Meningeal tumors histologically mimicking meningioma. *Pathol Res Pract.* 2012;208:567-77. (corresponding author)
63. **Barresi V**. Angiogenesis as a predictor of recurrence in meningiomas. *J Neurooncol.* 2011;101:169-170. (corresponding author; letter)
64. **Barresi V**, Reggiani-Bonetti L, Di Gregorio C, Ponz-De Leon M, Barresi G. Lymphatic vessel density and its prognostic value in stage I colorectal carcinoma. *J Clin Pathol.* 2011; 64:6-12. (corresponding author)
65. **Barresi V**, Vitarelli E, Tuccari G, Barresi G. MMP-9 expression in meningiomas: a prognostic marker for recurrence risk? *J Neurooncol* 2011; 102:189-196. (corresponding author)
66. **Barresi V**. Neo-angiogenesis in meningiomas: a review. *Brain Tumor Pathol* 2011;28:99-106. (corresponding author)
67. **Barresi V**, Reggiani-Bonetti L, Di Gregorio C, Vitarelli E, Ponz De Leon M, Barresi G. Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in stage I colorectal carcinoma. *Pathol Res Pract.* 2011;207:479-486. (corresponding author)
68. **Barresi V**, Ieni A, Regiani-Bonetti L, Di Gregorio C, Ponz de Leon Maurizio, Barresi G. Neutrophil gelatinase-associated lipocalin (NGAL): a new prognostic marker in stage I colorectal carcinoma? *Hum Pathol* 2011; 42:1720-1726. (corresponding author)
69. **Barresi V**, Caffo M, Ieni A, Alafaci C, Tuccari G. Osteoblastic meningiomas: clinico-pathological and immunohistochemical features of an uncommon variant. *J Neurooncol.* 2011; 105:225-232. (corresponding author)
70. **Barresi V**, Tuccari G. Meningioma with zell-ballen growth pattern: histological and immunohistochemical findings. *APMIS* 2011;119:815-817 (corresponding author; letter)
71. **Barresi V**, Vitarelli E, Cerasoli S, Barresi G. The cell growth inhibitory transcription factor C/EBPdelta is expressed in human meningiomas in association with low histological grade and proliferation index. *J Neurooncol.* 2010;97:233-240. (corresponding author)
72. **Barresi V**, Vitarelli E, Regiani-Bonetti L, Di Gregorio C, Ponz de Leon Maurizio, Barresi G. Stage I colorectal carcinoma: Vascular Endothelial Growth Factor (VEGF) immunohistochemical expression, microvessel density and their correlation with clinical outcome. *Virchows Arch.* 2010 Jul;457(1):11-9. (corresponding author)
73. **Barresi V**, Ieni A, Bolignano D, Magno C, Buemi M, Barresi G. Neutrophil gelatinase-associated lipocalin (NGAL) immunoexpression in renal tumors: correlation with histotype and histological grade. *Oncol Rep* 2010; 24:305-310 (corresponding author)
74. **Barresi V**, Barresi G. Endoglin: a marker of neoplasia or rather of neo-angiogenesis? *Head & Neck* 2010; 32:970-971 (corresponding author; letter)
75. **Barresi V**, Alafaci C, Caffo M, Tuccari G. Importance of intra-operative cytology in the definition of cystic solitary brain lesions. *Diagn Cytopathol* 2010; Nov;38(11):854-6 (corresponding author; letter)
76. **Barresi V**, Tuccari G. Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas. *Neuropathology* 2010; 30:547-556 (corresponding author)
77. **Barresi V**, Tuccari G, Barresi G. NGAL immunohistochemical expression in brain primary and metastatic tumours. *Clin Neuropathol* 2010; 29:317-322. (corresponding author)
78. **Barresi V**, Lucianò R, Vitarelli E, Labate A, Tuccari G, Barresi G. Neutrophil gelatinase-associated lipocalin immunoexpression in colorectal carcinoma: A stage specific prognostic factor? *Oncol Lett* 2010; 1:1089-1096. (corresponding author)
79. **Barresi V**, Vitarelli E, Cerasoli S. Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density. *Virchows Arch.* 2009;454:563-571 (corresponding author)
80. **Barresi V**, Buttarelli FR, Vitarelli E, Arcella A, Antonelli M, Giangaspero F. Cav-1 expression in diffuse gliomas: correlation with the proliferation index, EGFR, p53 and 1p/19q status. *Hum Pathol* 2009; 40:1738-1746. (corresponding author)
81. **Barresi V**, Ieni A, Magno C, Barresi G. High grade urothelial carcinoma of the urinary bladder showing acquisition of a microcystic histology in the penile metastasis: histogenetic considerations. *Pathol Res Pract* 2009;205:568-571. (corresponding author)

82. **Barresi V**, Ieni A, Macrì A, Grosso M. Clear cell colorectal carcinoma: a case report with analysis of neo-angiogenesis. *Int J Colorectal Dis* 2009 Nov;24(11):1351-2. (corresponding author; letter)
83. **Barresi V**, Grosso M, Giuffrè G, Tuccari G, Barresi G. The expression of adiponectin receptors Adipo-R1 and Adipo-R2 is associated with an intestinal histotype and a longer survival in gastric carcinoma. *J Clin Pathol* 2009; 62:705-709. (corresponding author)
84. **Barresi V**, Tuccari G, Barresi G. Adiponectin immunohistochemical expression in colorectal cancer and its correlation with the histological grade and tumor microvessel density. *Pathology* 2009; 41:533-538. (corresponding author)
85. **Barresi V**, Tuccari G. Evaluation of neo-angiogenesis in a case of chordoid meningioma. *J Neuro-Oncol* 2009;95:445-447. (corresponding author)
86. **Barresi V**, Vitarelli E, Tuccari G, Barresi G. Correlative study of microvessel density and 5-lipoxygenase expression in human sporadic colorectal cancer. *Arch Pathol Lab Med* 2008; 132:1807-1812 (corresponding author)
87. **Barresi V**, Vitarelli E, Barresi G. Acne inversa complicated by squamous cell carcinoma in association with diffuse malignant peritoneal mesothelioma arisen in the absence of predisposing factors: a case report. *J Cutan Pathol* 2008; 35:70-73. (corresponding author)
88. **Barresi V**, Tuccari G. Correlative evidence that tumour-cell derived caveolin-1 mediates angiogenesis. *Hum Pathology* 2008; 39:471-472 (corresponding author; letter)
89. **Barresi V**, Cerasoli S, Tuccari G. Correlative evidence that tumour cell-derived caveolin-1 mediates angiogenesis in meningiomas. *Neuropathology* 2008; 28:472-478. (corresponding author)
90. **Barresi V**, Grosso M, Barresi G. Immunohistochemical evidence of caveolin-1 expression in the human fetal and neonatal striated muscle and absence in the adult's. *Appl Imm Mol Morph* 2008; 16:267-273. (corresponding author)
91. **Barresi V**, Grosso M, Vitarelli E, Granese R, Barresi G. Endoglin (CD105) immunoexpression in human foetal and neonatal lung. *Histol Histopathol* 2008; 23:701-708. (corresponding author)
92. **Barresi V**, Alafaci C, Salpietro F, Tuccari G. SStr2A immunohistochemical expression in human meningiomas: Is there a correlation with the histological grade, proliferation or microvessel density? *Oncol Rep* 2008; 20:485-492. (corresponding author)
93. **Barresi V**, Giuffrè G, Vitarelli E, Todaro P, Tuccari G. Caveolin-1 immuno-expression in human gastric cancer: histopathogenetic hypotheses. *Virchows Arch* 2008; 453:571-578 (corresponding author)
94. **Barresi V**, Grosso M, Vitarelli E, Triolo O, Barresi G. Endoglin (CD105) expression in the human heart throughout gestation: an immunohistochemical study. *Reprod Sci* 2008; 15:1018-1026 (corresponding author)
95. **Barresi V**, Cerasoli S, Vitarelli E, Tuccari G. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas. *Acta neuropathol* 2007;114:147-156. (corresponding author)
96. **Barresi V**, Grosso M, Vitarelli E, Tuccari G, Barresi G. 5-Lipoxygenase is co-expressed with COX-2 in sporadic colorectal cancer: a correlation with advanced stage. *Dis Colon Rectum* 2007;50:1576-1584. (corresponding author)
97. **Barresi V**, Cerasoli S, Paioli G, Vitarelli E, Giuffrè G, Guiducci G, Tuccari G, Barresi G. Caveolin-1 in meningiomas: expression and clinico-pathological correlations. *Acta Neuropathol (Berl)*. 2006 Nov;112(5):617-26. (corresponding author)
98. **Barresi V**, Grosso M, Bulfamante G, Vitarelli E, Ghioni MC, Barresi G. Caveolin-1 immuno-expression in human fetal tissues during mid- and late gestation. *Eur J Histochem*. 2006 Jul-Sep;50(3):183-90. (corresponding author)
99. **Barresi V**, Cerasoli S, Morigi F, Cremonini AM, Volpini M, Tuccari G. Gliosarcoma With Features of Osteoblastic Osteosarcoma. A Review. *Arch Pathol Lab Med*. 2006 130(8): 1208-1211. (corresponding author)
100. **Barresi V**, Cerasoli S, Vitarelli E, Donati R. Spinal intradural mullerianosis: a case report. *Histol Histopathol*. 2006 Oct;21(10):1111-4. (corresponding author)
101. **Barresi V**, Vitarelli E, Grosso M, Tuccari G, Barresi G. Relationship between immunoexpression of mucin peptide cores MUC1 and MUC2 and Lauren's histologic subtypes of gastric carcinomas. *Eur J Histochem* 2006; Oct-Dec; 50(4): 301-310. (corresponding author)

Second author

1. Turri G, **Barresi V**, Valdegamberi A, Gecchele G, Conti C, Ammendola S, Guglielmi A, Scarpa A, Pedrazzani C. Clinical Significance of Preoperative Inflammatory Markers in Prediction of Prognosis in Node-Negative Colon Cancer: Correlation between Neutrophil-to-Lymphocyte Ratio and Poorly Differentiated Clusters. *Biomedicines*. 2021 Jan 19;9(1):94
2. Lombardi G, **Barresi V**, Castellano A, Tabouret E, Pasqualetti F, Salvalaggio A, Cerretti G, Caccese M, Padovan M, Zagonel V, Ius T. Clinical Management of Diffuse Low-Grade Gliomas. *Cancers (Basel)*. 2020 Oct 16;12(10):3008 (unico anatomopatologo tra gli autori).

3. Lombardi G, **Barresi V**, Indraccolo S, et al. Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. *Cancers (Basel)*. 2020;12(8):E2283. Published 2020 Aug 14. doi:10.3390/cancers12082283
4. Reggiani-Bonetti L, **Barresi V**, Manenti A, Domati F, Farinetti A. Histology of the mesorectal lymphatics explains aspects of rectal cancer. *Clin Res Hepatol Gastroenterol*. 2018 Mar 23. pii: S2210-7401(18)30037-8. doi:10.1016/j.clinre.2017.12.009 (letter).
5. Ieni A, **Barresi V**, Licata L, Cardia R, Fazzari C, Nuciforo G, Caruso F, Caruso M, Adamo V, Tuccari G. Immunoexpression of lactoferrin in triple-negative breast cancer patients: A proposal to select a less aggressive subgroup. *Oncol Lett*. 2017 May;13(5):3205-3209.
6. Ieni A, **Barresi V**, Reggiani Bonetti L, Branca G, Caruso RA, Tuccari G. Cytohistological and immunohistochemical characteristics of spindle-shaped mesenchymal neoplasms occurring in the gastrointestinal tract. *Scand J Gastroenterol*. 2017; 52(3):291-299
7. Ieni A, **Barresi V**, Cardia R, Licata L, Di Bari F, Benvenga S, Tuccari G. The micropapillary/hobnail variant of papillary thyroid carcinoma: A review of series described in the literature compared to a series from one southern Italy pathology institution. *Rev Endocr Metab Disord*. 2016; 17: 521-527
8. Ieni A, **Barresi V**, Branca G, Caruso RA, Tuccari G. Mast cell interaction with neutrophils in human gastric carcinomas: ultrastructural observations. *Anal Cell Pathol* 2016; 2016: 1691971
9. Ieni A, **Barresi V**, Rigoli L, Fedele F, Tuccari G, Caruso RA. Morphological and Cellular Features of Innate Immune Reaction in *Helicobacter pylori* Gastritis: A Brief Review. *Int J Mol Sci*. 2016 Jan 15;17(1).
10. Maccio L, **Barresi V**, Domati F, Martorana E, Cesinaro AM, Migaldi M, Iachetta F, Ieni A, Bonetti LR. Clinical significance of pelvic lymph node status in prostate cancer: review of 1690 cases. *Intern Emerg Med*. 2016 Apr;11(3):399-404.
11. Reggiani Bonetti L, **Barresi V**, Bettelli S, Domati F, Palmiere C. Poorly differentiated clusters (PDC) in colorectal cancer: what is and ought to be known. *Diagn Pathol*. 2016 Mar 22;11:31.
12. Arena S, **Barresi V**, Romeo C. Giant Angiofibroma of the Scrotum in a Child. *Urology*. 2016; 93:e15-16
13. Ieni A, **Barresi V**, Ricciardi GR, Adamo B, Adamo V, Tuccari G. Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about "Triple-negative breast cancer: treatment challenges and solutions" by Collignon et al. *Breast Cancer (Dove Med Press)*. 2016 Aug 19;8:157-9. (letter)
14. Ieni A, **Barresi V**, Tuccari G. Diagnostic relevance of cell block procedure in secondary tumors of the pancreas. *Cytojournal*. 2016 Aug 31;13:19. (letter)
15. Reggiani Bonetti L, **Barresi V**, Bertani A, Maccio L, Palmiere C. Human cytomegalovirus induced pseudotumor of upper gastrointestinal tract mucosa: effects of long-term chronic disease? *J Med Virol*. 2015 Jun;87(6):1041-5.
16. Arena S, **Barresi V**, Manganaro A, Vincenzo S, Perrone P, Gitto E, Romeo C. Bladder mass in newborn: case report and review of literature. *Urology*. 2015;86:1004-1007. doi: 10.1016/j.urology.2015.06.040.
17. Ieni A, **Barresi V**, Rigoli L, Caruso RA, Tuccari G. HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach. *Dis Markers*. 2015;2015:234851. (corresponding author)
18. Ieni A, **Barresi V**, Giuffrè G, Caltabiano R, Cascone A, Del Sordo R, Cabibi D, Zeppa P, Lanzafame S, Sidoni A, Franco V, Tuccari G. Letter to the Editor regarding the paper by Aurilio et al., A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. *Eur J Cancer*. 2014; 50: 1035-37 (letter)
19. Ieni A, **Barresi V**, Caltabiano R, Caleo A, Bonetti LR, Lanzafame S, Zeppa P, Caruso RA, Tuccari G. Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis. *Int J Mol Sci*. 2014 Dec 3;15(12):22331-41.
20. Ieni A, **Barresi V**, Caltabiano R, Cascone AM, Del Sordo R, Cabibi D, Zeppa P, Lanzafame S, Sidoni A, Franco V, Tuccari G. Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation. *Onco Targets Ther*. 2014 Jul11;7:1267-72.
21. Caffo M, **Barresi V**, Caruso G, Cutugno M, La Fata G, venza M, Alafaci C, Tomasello F. Innovative therapeutic strategies in the treatment of brain metastases. *Int J Mol Sci* 2013; 14 : 2135-2174
22. Ieni A, **Barresi V**, Branca G, Giuffrè G, Rosa MA, Tuccari G. Immunoexpression of lactoferrin in bone metastases and corresponding primary carcinomas. *Oncology Lett* 2013;5(5): 1536-1540
23. Saraceno G, **Barresi V**, Trimarchi F, Cannavo S. Occult leydig cell tumour and androgen-receptor positive breast cancer in a woman with severe hyperandrogenism. *J Ovarian Res*. 2013 Jul 1;6(1):43.
24. Ieni A, **Barresi V**, Giuffrè G, Caruso RA, Lanzafame S, Villari L, Salomone E, Roz E, Cabibi D, Franco V, Certo G, Labate A, Nagar C, Magliolo E, Broggi B, Fazzari C, Italia F, Tuccari G. HER2 status in

- advanced gastric carcinoma: A retrospective multicentric analysis from Sicily. *Oncol Lett.* 2013 Dec;6(6):1591-1594
25. Ieni A, **Barresi V**, Grosso M, Speciale G, Rosa MA, Tuccari G. Does Lactoferrin Behave as an Immunohistochemical Oncofetal Marker in Bone and Cartilage Human Neoplasms? *Pathol Oncol Res* 2011;17:287-293
 26. Ieni A, **Barresi V**, Grosso M, Tuccari G. Immunohistochemical evidence of lactoferrin in human embryo-foetal bone and cartilage tissues. *Cell Biol Int* 2010;34:845-849.
 27. Ieni A, **Barresi V**, Grosso M, Rosa MA, Tuccari G. Lactoferrin immuno-expression in human normal and neoplastic bone tissue. *J Bone Miner Metab* 2009;27:364-371. (corresponding author)
 28. Ieni A, **Barresi V**, Grosso M, Tuccari G. Immunolocalization of lactoferrin in cartilage-forming neoplasms. *J Orthop Sci* 2009;14:732-737.
 29. Giuffrè G, **Barresi V**, Catalano A, Cappiello A, Stagno d'Alcontres F, Tuccari G. Actinic keratosis associated with squamous and basal cell carcinomas: an evaluation of neoplastic progression by a standardized AgNOR analysis. *Eur J Histochem* 2008; 52: 53-60
 30. Famà F, **Barresi V**, Giuffrè G, Todaro P, Mazzei S, Vindigni A, Giofrè-Florio M. An unusual presentation of secondary involvement of chronic B-cell lymphocytic leukaemia. A case report. *Tumori* 2008; 94:617-620.
 31. Giuffrè G, **Barresi V**, Skliros C, Barresi G, Tuccari G. Immunoexpression of lactoferrin in human sporadic renal cell carcinoma. *Oncol Rep* 2007;17:1021-6.

Third author

1. Broggi G, Altieri R, **Barresi V**, Certo F, Barbagallo GMV, Zanelli M, Palicelli A, Magro G, Caltabiano R. Histologic Definition of Enhancing Core and FLAIR Hyperintensity Region of Glioblastoma, IDH-Wild Type: A Clinico-Pathologic Study on a Single-Institution Series. *Brain Sci.* 2023 Jan 31;13(2):248.
2. Wagner A, Gurzu S, **Barresi V**, Jiang Y. Editorial: Detection and characterization of gastrointestinal (early) cancer. *Front Oncol.* 2022 Nov 21;12:1089612. doi: 10.3389/fonc.2022.1089612
3. Paolino G, Pantanowitz L, **Barresi V**, Pagni F, Munari E, Moretta L, Brunelli M, Bariani E, Vigliar E, Pisapia P, Malapelle U, Troncone G, Girolami I, Eccher A. PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy. *Pathol Res Pract.* 2021 Oct;226:153605. doi: 10.1016/j.prp.2021.153605. Epub 2021 Sep 1.
4. Feletti A, Marrone F, **Barresi V**, Sala F. Hemangioblastoma with Contrast-Enhanced Cystic Wall: When the Surgical Rule Must Not Be Respected. *World Neurosurg.* 2021 May;149:190-194. doi: 10.1016/j.wneu.2021.02.111. Epub 2021 Mar 5. PMID: 33677088. (unico anatomopatologo tra gli autori)
5. Nicosia L, Bucpapaj R, **Barresi V**, Damante R, Napoli G, Ghimenton C, Giaj-Levra N, Cancedda M, Flaminio S, Figlia V, Alongi F. Resected atypical meningioma relapsed to anaplastic meningioma during luteinizing hormone-releasing hormone agonist therapy. *Neurochirurgie.* 2020 Oct 22:S0028-3770(20)30438-0
6. Shivji S, Conner JR, Barresi V, Kirsch R. Poorly differentiated clusters in colorectal cancer: a current review and implications for future practice [published online ahead of print, 2020 May 1]. *Histopathology.* 2020;10.1111/his.14128. doi:10.1111/his.14128
7. Girolami I, Parwani A, **Barresi V**, Marletta S, Ammendola S, Stefanizzi L, Novelli L, Capitanio A, Brunelli M, Pantanowitz L, Eccher A. The Landscape of Digital Pathology in Transplantation: From the Beginning to the Virtual E-Slide. *J Pathol Inform.* 2019 Jul 1;10:21. doi: 10.4103/jpi.jpi_27_19.
8. Domati F, Bonetti LR, **Barresi V**, Zizzo M, Manenti A. Radiation therapy damages external anal sphincter and perineal muscle floor. *J Surg Oncol.* 2018 Sep;118(4):718.
9. Ieni A, Angelico G, **Barresi V**, Giuffrè G, Arena F, Caruso RA, Tuccari G. Human Epidermal Growth Factor Receptor 2 Status in Gastric Carcinomas with Distinctive Prevalent Cribriform Component. *Dis Markers* 2018 2018:1505428
10. Caffo M, Rinaldi M, **Barresi V**, Caruso G, Cardali SM, Esposito E, Mallamace R, Campolo M, Casili G, Conti A, Germanò A, Cuzzocrea S, Minutoli L. Modulation of Dkk-3 and claudin-5 as new therapeutic strategy in the treatment of meningioma. *Oncotarget* 2017 Aug 7;8(40):68280-68290 (unico anatomo-patologo tra gli autori)
11. Santoro G, Laganà AS, Micali A, **Barresi V**, Giacobbe V, Palmara V. Historical, morphological and clinical overview of placental site trophoblastic tumors: from bench to bedside. *Arch Gynecol Obstet.* 2017;295:173-187
12. Santamaria A, Laganà AS, **Barresi V**, Triolo O, Fondacaro NS, Corrado F. Prenatally identified Pallister-Killian syndrome: Ultrasound pattern and diagnostic considerations. *J Obstet Gynaecol.* 2016; 36: 406-407

13. Caffo M, Caruso G, **Barresi V**, Tomasello F. Ossified intracranial meningiomas: description of the first series of cases and review of the literature. *World Neurosurg* 2016; 94:458-464
14. Caltabiano R, Puzzo L, **Barresi V**, Ieni A, Loreto C, Musumeci G, Castrogiovanni P, Ragusa M, Foti P, Russo A, Longo A, Reibaldi M. ADAM 10 expression in primary uveal melanoma as prognostic factor for risk of metastasis. *Pathol Res Pract*. 2016; 212: 980-987
15. Morabito R, Grasso G, **Barresi V**, La Spina P, Garufi G, Alafaci E, Salpietro FM, Longo M, Granata F, Alafaci C. Intracranial venous sinus thrombosis as unusual presentation of Bing-Neel syndrome: case illustration. *J Neurosurg*. 2016 Dec 2:1-2
16. Lupo F, Scarcella MC, **Barresi V**, d'Alcontres FS, Colonna MR, Delia G. Anatomical and aesthetical reconstruction of complex hair-bearing areas: a three-step procedure including implant of dermal regeneration templates, skin grafting, and hair micrografting. *J Craniofac Surg*. 2015 May;26(3):719-21
17. Campenni A, Caruso G, **Barresi V**, Pino M, Cucinotta M, Baldari S, Caffo M. Gliomas with intratumoral abscess formation: Description of new cases, review of the literature, and the role of (99m)TC-Leukoscan. *Kaohsiung J Med Sci*. 2015 Jul;31(7):377-83
18. Caltabiano R, Puzzo L, **Barresi V**, Cardile V, Loreto C, Ragusa M, Russo A, Reibaldi M, Longo A. Expression of Raf Kinase Inhibitor Protein (RKIP) is a predictor of uveal melanoma metastasis. *Histol Histopathol*. 2014;29:1325-34
19. Branca G, Irato E, **Barresi V**, De Marco M, Guccione F, Palmeri R. A rare case of male breast cavernous-type angioleiomyoma. *Tumori*. 2014 Jul-Aug;100(4):148e-52e
20. Giuffrè G, Ieni A, **Barresi V**, Caruso RA, Tuccari G. HER2 status in unusual histological variants of gastric adenocarcinomas. *J Clin Pathol* 2012; 65:237-241
21. Alafaci C, Caffo M, **Barresi V**, Cutugno M, Pino MA, Granata F, De Ponte FS, Salpietro FM, Tomasello F. Large trigeminal schwannoma of the infratemporal fossa: Evaluation of neoangiogenesis in this rare neoplasm. *Head Neck*. 2012 Sep 10. doi: 10.1002/hed.23142.
22. Granese R, Cucinella G, **Barresi V**, Navarra G, Candiani M, Triolo O. Isolated endometriosis on the rectus abdominis muscle in women without a history of abdominal surgery: a rare and intriguing finding. *J Minim Invasive Gynecol*. 2009 Nov-Dec;16(6):798-801.
23. Giuffrè G, Mormandi F, **Barresi V**, Bordi C, Tuccari G, Barresi G. Quantity of AgNORs in gastric endocrine carcinoid tumours as a potential prognostic tool. *Eur J Histochem*. 2006 Jan-Mar;50(1):45-50.

Last author

1. Marastoni E, Ammendola S, Rossi S, Giovannoni I, Broggi G, Masotto B, Feletti A, **Barresi V**. H3 K27M mutation in rosette-forming glioneuronal tumors: a potential diagnostic pitfall. *Virchows Arch*. 2024 Jan 17. doi: 10.1007/s00428-024-03739-2 (corresponding author)
2. Marastoni E, **Barresi V**. Atypical meningioma: Histopathological, genetic, and epigenetic features to predict recurrence risk. *Histol Histopathol*. 2023 Oct 20:18670 (corresponding author)
3. Martelli FM, Marastoni E, **Barresi V**. A diffuse glioma with oligodendroglial-like cells and extensive calcifications. *Brain Pathol*. 2023 Jul 6. doi: 10.1111/bpa.13187
4. Broggi G, **Barresi V**. Assessment of CDKN2A/B homozygous deletion in gliomas: To FISH or not to FISH? *J Neuropathol Exp Neurol*. 2023 2023 Jul 20;82(8):742-744. (corresponding author)
5. Marastoni E, **Barresi V**. Meningioma Grading beyond Histopathology: Relevance of Epigenetic and Genetic Features to Predict Clinical Outcome. *Cancers (Basel)*. 2023 May 27;15(11):2945 (corresponding author)
6. Caffo M, Minutoli L, Tabouret E, **Barresi V**. Editorial: Novel diagnostic and therapeutic strategies in the management of cerebral gliomas. *Front Oncol*. 2023 Jan 12;12:1115410.
7. Ammendola S, Broggi G, **Barresi V**. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification. *Histol Histopathol*. 2023 023 Jul;38(7):739-753 (corresponding author)
8. Ammendola S, Caldonazzi N, Rizzo PC, Turri G, Pedrazzani C, **Barresi V**. H3K27me3 Immunohistochemical Loss Predicts Lower Response to Neo-Adjuvant Chemo-Radiotherapy in Rectal Carcinoma. *Biomedicines*. 2022 Aug 21;10(8):2042. doi: 10.3390/biomedicines10082042. PMID: 36009589; PMCID: PMC9405749
9. Ammendola S, Rizzo PC, Longhi M, Zivelonghi E, Pedron S, Pinna G, Sala F, Nicolato A, Scarpa A, **Barresi V**. The Immunohistochemical Loss of H3K27me3 in Intracranial Meningiomas Predicts Shorter Progression-Free Survival after Stereotactic Radiosurgery. *Cancers (Basel)*. 2022 Mar 28;14(7):1718. doi: 10.3390/cancers14071718. PMID: 35406488; PMCID: PMC8997117 (corresponding author)
10. Ammendola S, **Barresi V**. Timing of H3K27me3 loss in secondary anaplastic meningiomas. *Brain Tumor Pathol*. 2022 Jul;39(3):179-18 PMID: 34988691 (letter; corresponding author)

11. Ammendola S, Simbolo M, Ciaparrone C, Rizzo PC, Caffo M, Pinna G, Sala F, Scarpa A, **Barresi V**. Intraventricular Meningiomas: Clinical-Pathological and Genetic Features of a Monocentric Series. *Curr Oncol*. 2022 Jan 2;29(1):178-185. doi: 10.3390/currenol29010017. PMID: 35049691; PMCID: PMC8775267 (Corresponding author)
12. Ammendola S, Caldonazzi N, Simbolo M, Piredda ML, Brunelli M, Poliani PL, Pinna G, Sala F, Ghimenton C, Scarpa A, **Barresi V**. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. *Virchows Arch*. 2021; 2021 Nov;479(5):987-996
13. Ammendola S, Bariani E, Eccher A, Capitanio A, Ghimenton C, Pantanowitz L, Parwani A, Girolami I, Scarpa A, **Barresi V**. The histopathological diagnosis of atypical meningioma: glass slide versus whole slide imaging for grading assessment. *Virchows Arch*. 2020; 478(4):747-756
14. Ammendola, S., Turri, G., Marconi, I., Burato, G., Pecori, S., Tomezzoli, A., Conti, C., Pedrazzani, C., & **Barresi, V.** (2020). The presence of poorly differentiated clusters predicts survival in stage II colorectal cancer. *Virchows Archiv : an international journal of pathology*, 478(2):241-248 (corresponding author)
15. Fioravanzo A, Caffo M, Di Bonaventura R, Gardiman MP, Ghimenton C, Ius T, Maffei V, Martini M, Nicolato A, Pallini R, Pegolo E, Pinna G, Sala F, Skrap M, Volpin V, **Barresi V**. A Risk Score Based on 5 Clinico-Pathological Variables Predicts Recurrence of Atypical Meningiomas. *J Neuropathol Exp Neurol*. 2020; 79(5):500-507 (corresponding author)
16. Fioravanzo A, Simbolo M, Giampiccolo D, Damante R, Pinna G, Scarpa A, **Barresi V**. Glioblastoma with tumor-to-tumor metastasis from lung adenocarcinoma. *Neuropathology*. 2019; 2019 Dec;39(6):474-478 (corresponding author)
17. Bernasconi R, Eccher A, Girolami I, Boldrini M, Masotto B, **Barresi V**. Extra-axial astroblastoma in a 67-year-old woman. *Neuropathology* 2019; 39(4):307-312 (corresponding author)
18. Lioni S, La Rocca L, Nunnari CM, **Barresi V**. Strong androgen receptor expression is not useful in distinguishing GATA3 + metastases. *Pathol Res Pract*. 2018; 214(12):2110-2114 (corresponding author)
19. Lioni S, Ieni A, Cannavò S, **Barresi V**. Immunohistochemical expression of glypican-3 in adrenocortical carcinoma: A potential cause of diagnostic pitfalls. *Ann Diagn Pathol* 2018; 35:92-93 (corresponding author)
20. Lioni S, Reggiani Bonetti L, Bettelli S, Spallanzani A, Gelsomino F, **Barresi V**. Histopathological variables in liver metastases of patients with stage IV colorectal cancer: Potential prognostic relevance of poorly differentiated clusters. *Hum Pathol*. 2018; 78:115-124. (corresponding author)
21. Reggiani Bonetti L, Lioni S, Vitarelli E, **Barresi V**. Prognostic significance of CDX2 immunoexpression in poorly differentiated clusters of colorectal carcinoma. *Virchows Arch*. 2017;471: 731-741 (corresponding author)
22. Reggiani Bonetti L, Lioni S, Domati F, Pagliani G, Mattioli E, **Barresi V**. Histological grading based on poorly differentiated clusters (PDC) is predictive of tumor response and clinical outcome in rectal carcinoma treated with neo-adjuvant chemo-radiotherapy. *Histopathology*. 2017;71:393-405 (corresponding author)
23. Reggiani Bonetti L, Lioni S, Domati F, **Barresi V**. Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery? *World J Gastroenterol* 2017; 23:1412-1423 (corresponding author)
24. Branca G, **Barresi V**. Mullerianosis of the urinary bladder. A rare tumorlike lesion. *Arch Pathol Lab Med* 2014;138:432-436 (corresponding author)
25. Baron L, Branca G, Trombetta C, Punzo E, Quarto F, Speciale G, **Barresi V**. Intestinal anisakidosis: histopathological findings and differential diagnosis. *Pathol Res Pract*. 2014 Nov;210(11):746-50. (corresponding author)

Collaborator

1. Ius T, Montemurro N, Lombardi G, Berardinelli J, Romano A, **Barresi V**, Cerretti G, Guarnera A, Tel A, Cavallo LM, Pasqualetti F, Feletti A. Decoding the puzzle: A multidisciplinary systematic review of adult brainstem glioma. *Crit Rev Oncol Hematol*. 2024 Feb 22;196:104261. doi: 10.1016/j.critrevonc.2024.104261 (unico anatomopatologo tra gli autori)
2. Mirian C, Jensen LR, Juratli TA, Maier AD, Torp SH, Shih HA, Morshed RA, Young JS, Magill ST, Bertero L, Stummer W, Spille DC, Brokinkel B, Oya S, Miyawaki S, Saito N, Proescholdt M, Kuroi Y, Gousias K, Simon M, Moliterno J, Prat-Acin R, Goutagny S, Prabhu VC, Tsiang JT, Wach J, Güresir E, Yamamoto J, Kim YZ, Lee JH, Koshy M, Perumal K, Baskaya MK, Cannon DM, Shrieve DC, Suh

- CO, Chang JH, Kamenova M, Straumann S, Soleman J, Eyüpoglu IY, Catalan T, Lui A, Theodosopoulos PV, McDermott MW, Wang F, Guo F, Góes P, de Paiva Neto MA, Jamshidi A, Komotar R, Ivan M, Luther E, Souhami L, Guiot MC, Csonka T, Endo T, Barrett OC, Jensen R, Gupta T, Patel AJ, Klisch TJ, Kim JW, Maiuri F, **Barresi V**, Tabernero MD, Skyrman S, Broechner A, Bach MJ, Law I, Scheie D, Kristensen BW, Munch TN, Meling T, Fugleholm K, Blanche P, Mathiesen T. The importance of considering competing risks in recurrence analysis of intracranial meningioma. *J Neurooncol*. 2024 Feb;166(3):503-511. doi: 10.1007/s11060-024-04572-y
3. Broggi G, Angelico G, Farina J, Tinnirello G, **Barresi V**, Zanelli M, Palicelli A, Certo F, Barbagallo G, Magro G, Caltabiano R. Tumor-associated microenvironment, PD-L1 expression and their relationship with immunotherapy in glioblastoma, IDH-wild type: A comprehensive review with emphasis on the implications for neuropathologists. *Pathol Res Pract*. 2024 Jan 16;254:155144. doi: 10.1016/j.prp.2024.155144.
 4. Arpa G, Vanoli A, Antoci F, Lenti MV, Di Sabatino A; and the Small Bowel Carcinoma Consortium. A Clinicopathologic Comparison Between Early-Onset and Late-Onset Small Bowel Adenocarcinoma: A Multicenter International Study. *Am J Gastroenterol*. 2024 Jan 1. doi: 10.14309/ajg.0000000000002585.
 5. Cerretti G, Pessina F, Franceschi E, **Barresi V**, Salvalaggio A, Padovan M, Manara R, Di Nunno V, Bono BC, Librizzi G, Caccese M, Scorsetti M, Maccari M, Minniti G, Navarra P, Lombardi G. Spinal ependymoma in adults: from molecular advances to new treatment perspectives. *Front Oncol*. 2023 Nov 24;13:1301179. doi: 10.3389/fonc.2023.1301179.
 6. Caruso G, Ferrarotto R, Curcio A, Metro L, Pasqualetti F, Gaviani P, **Barresi V**, Angileri FF, Caffo M. Novel Advances in Treatment of Meningiomas: Prognostic and Therapeutic Implications. *Cancers (Basel)*. 2023 Sep 12;15(18):4521 (unico anatomopatologo tra gli autori).
 7. Turri G, Caligola S, Ugel S, Conti C, Zenuni S, **Barresi V**, Ruzzenente A, Lippi G, Scarpa A, Bronte V, Guglielmi A, Pedrazzani C. Pre-diagnostic prognostic value of leukocytes count and neutrophil-to-lymphocyte ratio in patients who develop colorectal cancer. *Front Oncol*. 2023 Jun 5;13:1148197.
 8. Minasi S, Gianno F, Bargiacchi L, **Barresi V**, Miele E, Antonelli M, Buttarelli FR. Case report of a pediatric medulloblastoma with concurrent MYC and MYCN subclonal amplification in distinct populations of neoplastic cells. *Virchows Arch*. 2023 May 22. doi: 10.1007/s00428-023-03560-3. Epub ahead of print. PMID: 37212894.
 9. Caffo M, Fusco R, Siracusa R, Caruso G, **Barresi V**, Di Paola R, Cuzzocrea S, Germanò AF, Cardali SM. Molecular Investigation of DKK3 in Cerebral Ischemic/Reperfusion Injury. *Biomedicines*. 2023 Mar 7;11(3):815. doi: 10.3390/biomedicines11030815.
 10. Di Bonaventura R, Martini M, Cenci T, Caccavella VM, **Barresi V**, Gessi M, Albanese A, Lauretti L, Pallini R, D'Alessandris QG, Olivi A. Dissecting Stemness in Aggressive Intracranial Meningiomas: Prognostic Role of SOX2 Expression. *Int J Mol Sci*. 2022 Oct 2;23(19):11690.
 11. Canet-Jourdan C, Pagès DL, Nguyen-Vigouroux C, Cartry J, Zajac O, Desterke C, Lopez JB, Gutierrez-Mateyron E, Signolle N, Adam J, Raingeaud J, Polrot M, Gonin P, Mathieu JRR, Souquere S, Pierron G, Gelli M, Dartigues P, Ducreux M, **Barresi V**, Jaulin F. Patient-derived organoids identify an apico-basolateral polarity switch associated with survival in colorectal cancer. *J Cell Sci*. 2022 Jun 15;jcs.259256. doi: 10.1242/jcs.259256. Epub ahead of print.
 12. Cardali SM, Caffo M, Caruso G, Scalia G, Gorgoglione N, Conti A, Vinci SL, **Barresi V**, Granata F, Ricciardo G, Garufi G, Raffa G, Germanò A. Cisternostomy for malignant middle cerebral artery infarction: proposed pathophysiological mechanisms and preliminary results. *Stroke Vasc Neurol*. 2022 Jun 7;svn-2021-000918. doi: 10.1136/svn-2021-000918. Epub ahead of print (unico anatomopatologo tra gli autori)
 13. Zwager LW, Bastiaansen BAJ, Montazeri NSM, Hompes R, **Barresi V**, Ichimasa K, Kawachi H, Machado I, Masaki T, Sheng W, Tanaka S, Togashi K, Yasue C, Fockens P, Moons LMG, Dekker E. Deep submucosal invasion is not an independent risk factor for lymph node metastasis in T1 colorectal cancer: a meta-analysis. *Gastroenterology*. 2022 163(1):174-189.
 14. Caramaschi S, Mangogna A, Salviato T, Ammendola S, **Barresi V**, Manco G, Canu PG, Zanelli G, Bonetti LR. Cytoproliferative activity in colorectal poorly differentiated clusters: Biological significance in tumor setting. *Ann Diagn Pathol*. 2021 Jun 16;53:151772. doi: 10.1016/j.anndiagpath.2021.151772.
 15. Arpa G, Vanoli A, Grillo F, Fiocca R, Klersy C, Furlan D, Sessa F, Ardizzone S, Sampietro G, Macciomei MC, Nesi G, Tonelli F, Capella C, Latella G, Ciardi A, Caronna R, Lenti MV, Ciccocioppo R, **Barresi V**, Malvi D, D'Errico A, Rizzello F, Poggioli G, Mescoli C, Rugge M, Luinetti O, Paulli M, Di Sabatino A, Solcia E. Prognostic relevance and putative histogenetic role of cytokeratin 7 and MUC5AC expression in Crohn's disease-associated small bowel carcinoma. *Virchows Arch*. 2021; 479(4):667-678 doi: 10.1007/s00428-021-03109-2
 16. Ius T, Tel A, Minniti G, Somma T, Solari D, Longhi M, De Bonis P, Scerrati A, Caccese M, **Barresi V**, Fiorentino A, Gorgoglione L, Lombardi G, Robiony M. Advances in Multidisciplinary Management of

- Skull Base Meningiomas. *Cancers (Basel)*. 2021 May 28;13(11):2664. doi: 10.3390/cancers13112664 (unico anatomopatologo tra gli autori)
17. Haddad TS, Lugli A, Aherne S, **Barresi V**, Terris B, Bokhorst JM, Brockmoeller SF, Cuatrecasas M, Simmer F, El-Zimaity H, Fléjou JF, Gibbons D, Cathomas G, Kirsch R, Kuhlmann TP, Langner C, Loughrey MB, Riddell R, Ristimäki A, Kakar S, Sheahan K, Treanor D, van der Laak J, Vieth M, Zlobec I, Nagtegaal ID. Improving tumor budding reporting in colorectal cancer: a Delphi consensus study. *Virchows Arch*. 2021; 479(3):459-469
 18. Re A, Ferraù F, Cafiero C, Spagnolo F, **Barresi V**, Romeo DP, Ragonese M, Grassi C, Pontecorvi A, Farsetti A, Cannavò S. Somatic Deletion in Exon 10 of Aryl Hydrocarbon Receptor Gene in Human GH-Secreting Pituitary Tumors. *Front Endocrinol (Lausanne)*. 2020 Nov 12;11:591039. doi: 10.3389/fendo.2020.591039. (unico anatomopatologo tra gli autori)
 19. Neri G, Arpa G, Guerini C, Grillo F, Lenti MV, Giuffrida P, Furlan D, Sessa F, Quaquarelli E, Viglio A, Ubezio C, Pasini A, Ferrero S, Sampietro G, Ardizzone S, Latella G, Mescoli C, Rugge M, Zingone F, **Barresi V**, Ciccocioppo R, Pedrazzoli P, Corazza GR, Luinetti O, Solcia E, Paulli M, Di Sabatino A, Vanoli A. Small Bowel Adenocarcinomas Featuring Special AT-Rich Sequence-Binding Protein 2 (SATB2) Expression and a Colorectal Cancer-Like Immunophenotype: A Potential Diagnostic Pitfall. *Cancers (Basel)*. 2020 Nov 19;12(11):E3441.
 20. Vanoli A, Grillo F, Guerini C, et al. Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas *Ann Surg Oncol*. 2020; 28(2):1167-1177
 21. Girolami I, Marletta S, Pantanowitz L, Torresani E, Ghimenton C, Barbareschi M, Scarpa A, Brunelli M, **Barresi V**, Trimboli P, Eccher A. Impact of Image Analysis and Artificial Intelligence in Thyroid Pathology, with particular reference to cytological aspects. *Cytopathology*. 2020 Sep;31(5):432-444
 22. Giuffrida P et al. PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability. *Mod Pathol*. 2020 Jul;33(7):1453
 23. La Rocca G, Sabatino G, Menna G, Altieri R, Ius T, Marchese E, Olivi A, **Barresi V**, Della Pepa GM. 5-Aminolevulinic Acid False Positives in Cerebral Neuro-Oncology: Not All That Is Fluorescent Is Tumor. A Case-Based Update and Literature Review. *World Neurosurg*. 2020 Feb 10;137:187-193 (Unico anatomopatologo tra gli autori)
 24. Sapienza D, Asmundo A, Silipigni S, Barbaro U, Cinquegrani A, Granata F, **Barresi V**, Gualniera P, Bottari A, Gaeta M. Feasibility Study of MRI Muscles Molecular Imaging in Evaluation of Early Post-Mortem Interval. *Sci Rep*. 2020 Jan 15;10(1):392. doi: 10.1038/s41598-019-57357-z (Unico anatomopatologo tra gli autori)
 25. D'Antonio A, Caputo A, Fraggetta F, Pepe P, Insabato L, Barra E, **Barresi V**, Altieri V, Greco U, Savastano R, Zeppa P. KPNA2/ERG Coexpression is Associated With Early Recurrence in Advanced Prostate Cancers. *Appl Immunohistochem Mol Morphol*. 2020 Jan;28(1):62-66.
 26. Caffo M, Cardali SM, Raffa G, Caruso G, **Barresi V**, Ricciardo G, Gorgoglione N, Granata F, Germanò A. The Value of Preoperative Planning Based on Navigated Transcranial Magnetic Stimulation for Surgical Treatment of Brain Metastases Located in the Perisylvian Area. *World Neurosurg*. 2020 Feb;134:e442-e452 (Unico anatomopatologo tra gli autori)
 27. Girolami I, Pantanowitz L, Marletta S, Brunelli M, Mescoli C, Parisi A, **Barresi V**, Parwani A, Neil D, Scarpa A, Rossi ED, Eccher A. Diagnostic concordance between whole slide imaging and conventional light microscopy in cytopathology: A systematic review. *Cancer Cytopathol*. 2019; 128(1):17-28.
 28. Villa C, Vasiljevic A, Jaffrain-Rea ML, Ansorge O, Asioli S, **Barresi V**, Chinezu L, Gardiman MP, Lania A, Lapshina AM, Poliani L, Reiniger L, Righi A, Saeger W, Soukup J, Theodoropoulou M, Uccella S, Trouillas J, Roncaroli F. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. *Virchows Arch*. 2019 475(6):687-692
 29. Remo A, Fassan M, Vanoli A, Reggiani Bonetti L, **Barresi V**, Tatangelo A, Gafà R, Guido G, Pancione M, Grillo F, Mastracci L. Special Histotypes of Colorectal Carcinoma Morphology and Molecular Features. *Cancers* 2019 Jul 23;11(7):1036
 30. Casili G, Caffo M, Campolo M, **Barresi V**, Caruso G, Cardali SM, Lanza M, Mallamace R, Filippone A, Conti A, Germanò A, Cuzzocrea S, Esposito E. TLR-4/Wnt modulation as new therapeutic strategy in the treatment of glioblastomas. *Oncotarget*. 2018 Dec 25;9(101):37564-37580 (unico anatomopatologo tra gli autori)
 31. Scaroni C, Albiger N, Daniele A, Dassie F, Romualdi C, Vazza G, Regazzo D, Ferraù F, **Barresi V**, Maffei V, Gardiman MP, Cannavò S, Maffei P, Ceccato F, Losa M, Occhi G. Paradoxical GH increase during OGTT is associated to first-generation somatostatin analogs responsiveness in acromegaly. *J Clin Endocrinol Metab*. 2018; 104(3):856-862

32. Polito F, Cucinotta M, Abbritti RV, Brogna A, Pergolizzi S, Tomasello C, **Barresi V**, Angileri FF, Di Giorgio R, Conti A, La Torre D, Germanò A, Aguenouz M. Silencing of telomere-binding protein adrenocortical dysplasia (ACD) homolog enhances radiosensitivity in glioblastoma cells. *Transl Res*. 2018 Jul 20. pii: S1931-5244(18)30106-3. doi: 10.1016/j.trsl.2018.07.005. (unico anatomopatologo tra gli autori)
33. Priola SM, Esposito F, Cannavò S, Conti A, Abbritti RV, **Barresi V**, Baldari S, Ferrau F, Germanò A, Tomasello F, Angileri FF. Aggressive Pituitary Adenomas: The Dark Side of the Moon. *World Neurosurg*. 2017 Jan;97:140-155. (unico anatomopatologo tra gli autori)
34. Conti A, Romeo SG, Cama A, La Torre D, **Barresi V**, Pezzino G, Tomasello C, Cardali S, Angileri FF, Polito F, Ferlazzo G, Di Giorgio R, Germanò A, Aguenouz M. MiRNA expression profiling in human gliomas: upregulated miR-363 increases cell survival and proliferation. *Tumour Biol*. 2016;37(10):14035-14048. (unico anatomopatologo tra gli autori)
35. Iachetta F, Domati F, Reggiani-Bonetti L, **Barresi V**, Magnani G, Marcheselli L, Cirilli C, Pedroni M. Prognostic relevance of microsatellite instability in pT3N0M0 colon cancer: a population-based study. *Intern Emerg Med*. 2016;11:41-46
36. Rinaldi M, Caffo M, Minutoli L, Marini H, Abbritti RV, Squadrito F, Trichilo V, Valenti A, **Barresi V**, Altavilla D, Passalacqua M, Caruso G. ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies. *Int J Mol Sci*. 2016 Jun 22;17(6). (unico anatomopatologo tra gli autori)
37. Romeo SG, Conti A, Polito F, Tomasello C, **Barresi V**, La Torre D, Cucinotta M, Angileri FF, Bartolotta M, Di Giorgio RM, Aguenouz M. miRNA regulation of Sirtuin-1 expression in human astrocytoma. *Oncol Lett*. 2016 Oct;12(4):2992-2998. (unico anatomopatologo tra gli autori)
38. Cannavo S, Messina E, Albani A, Ferrau F, **Barresi V**, Priola S, Esposito F, Angileri F. Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide. *Endocrine*. 2016;52:481-487 (unico anatomopatologo tra gli autori)
39. Ieni A, Todaro P, Crino SF, **Barresi V**, Tuccari G. Endoscopic ultrasound-guided fine-needle aspiration cytology in pancreaticobiliary carcinomas: diagnostic efficacy of cell-block immunocytochemistry. *Hepatobiliary Pancreat Dis Int*. 2015 Jun;14(3):305-12
40. Caruso G, Elbabaa SK, Gonzalez-Lopez P, **Barresi V**, Passalacqua M, Caffo M. Innovative Therapeutic Strategies in the Treatment of Meningioma. *Anticancer Res* 2015 Dec;35(12):6391-400. (unico anatomopatologo tra gli autori)
41. Reggiani-Bonetti L, Di Gregorio C, Pedroni M, Domati F, **Barresi V**, Marcheselli L, Ponz de Leon M. Incidence trend of malignant polyps through the data of a specialized colorectal cancer registry: clinical features and effect of screening. *Scand J Gastroenterol*. 2013 Nov;48(11):1294-301.
42. Nania A, Granata F, Vinci S, Pitrone A, **Barresi V**, Morabito R, Settineri N, Tomasello F, Alafaci C, Longo M. Necrosis Score, Surgical Time, and Transfused Blood Volume in Patients Treated with Preoperative Embolization of Intracranial Meningiomas. Analysis of a Single-Centre Experience and a Review of Literature. *Clin Neuroradiol*. 2014;24:29-36. (unico anatomopatologo tra gli autori)
43. Gessi M, van de Nes J, Griewank K, **Barresi V**, Buckland ME, Kirfel J, Caltabiano R, Hammes J, Lauriola L, Pietsch T, Waha A. Absence of TERT promoter mutations in primary melanocytic tumors of the central nervous system. *Neuropathol Appl Neurobiol*. 2014; 40:794-797 (letter)
44. Caffo M, Caruso G, Fata GL, **Barresi V**, Visalli M, Venza M, Venza I. Heavy metals and epigenetic alterations in brain tumors. *Curr Genomics*. 2014 Dec;15(6):457-63. (unico anatomopatologo tra gli autori)
45. Trovato M, Torre ML, Ragonese M, Simone A, Scarfi R, **Barresi V**, Giuffrè G, Benvenga S, Angileri FF, Tuccari G, Trimarchi F, Ruggeri RM, Cannavò S. HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies. *Endocrine*. 2013; 44: 735-743.
46. Cannavo S, Ferrau F, Cotta OR, Saitta S, **Barresi V**, Cristani MT, Saija A, Ruggeri RM, Trimarchi F, Gangemi S. Increased serum interleukin-22 levels in patients with PRL-secreting and non-functioning pituitary macroadenomas. *Pituitary*. 2013; 17: 76-80. (unico anatomopatologo tra gli autori)
47. Cassarino MF, Ambrogio AG, Pagliardini L, De Martin M, **Barresi V**, Cavagnini F, Pecori Giraldi F. ACTH-Secreting Pheochromocytoma with False-Negative ACTH Immunohistochemistry. *Endocr Pathol*. 2012;23: 1091-1095 (unico anatomopatologo tra gli autori)
48. Reggiani Bonetti L, Migaldi M, Caredda E, Boninsegna A, Ponz De Leon M, Di Gregorio C, **Barresi V**, Scannone D, Danese S, Cittadini A, Sgambato A. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients. *Scand J Gastroenterol*. 2012;47:1211-7.

49. Reggiani Bonetti L, Di Gregorio C, De Gaetani C, Pezzi A, Barresi G, **Barresi V**, Roncucci L, Ponz de Leon M. Lymph node micrometastasis and survival of patients with Stage I (Dukes' A) colorectal carcinoma. *Scand J Gastroenterol*. 2011;46:881-886.
50. Catalfamo L, Lombardo G, Nava C, Familiari E, Petrocelli M, Iudicello V, Ieni A, **Barresi V**, De Ponte FS. Tongue schwannoma: clinicopathological findings. *J Craniofac Surg*. 2011 May;22(3):1158-61.
51. Alafaci C, Caffo M, Caruso G, **Barresi V**, Cutugno M, Salpietro FM, Tomasello F. Brain metastases as first clinical manifestation of ovarian carcinoma. *Clin Neuropathol*. 2011 Jul-Aug;30(4):203-5. (letter; unico anatomopatologo tra gli autori)
52. Giuffrè G, Adamo V, Ieni A, Colanese F, **Barresi V**, Caristi N, Adamo B, Tuccari G. Hematopoietic progenitor cells (HPCs) in node-negative invasive breast carcinomas: Immunohistochemical analysis and clinico-pathological correlations. *Pathol Res Pract*. 2011 Aug 15;207(8):487-91.
53. C. Serradifalco, P. Catanese, L. Rizzuto, F. Cappello, R. Puleio, **V. Barresi**, C. M. Nunnari, G. Zummo, V. Di Felice. Embryonic and foetal Islet-1 positive cells in human hearts are also positive to c-Kit. *Eur J Histochem* 2011; 55:229-234 (unico anatomopatologo tra gli autori)
54. Sindoni A, Rizzo M, Tuccari G, Ieni A, **Barresi V**, Calbo L, Cucinotta E, Trimarchi F, Benvenaga S. Thyroid metastases from renal cell carcinoma: review of the literature. *Scientific World Journal*. 2010 Apr 1;10:590-602.
55. Sindoni A, Rizzo M, Tuccari G, Ieni A, **Barresi V**, Calbo L, Cucinotta E, Mallamace A, Trimarchi F, Benvenaga S. Thyroid metastases from clear cell renal carcinoma 18years after nephrectomy. *Ann Endocrinol (Paris)*. 2010;71:127-130.
56. Ruggeri RM, Ferraù F, Campennì A, Simone A, **Barresi V**, Giuffrè G, Tuccari G, Baldari S, Trimarchi F. Immunohistochemical localization and functional characterization of somatostatin receptor subtypes in a corticotrophin releasing hormone-secreting adrenal pheochromocytoma: review of the literature and report of a case. *Eur J Histochem* 2009;53:1-6
57. Familiari L, Strangio G, Consolo P, Luigiano C, Bonica M, Barresi G, **Barresi V**, Familiari P, D'Arrigo G, Alibrandi A, Birilli A, Fries W, Scaffidi M. Optical coherence tomography (OCT) evaluation of ulcerative colitis: the patterns and the comparison with histology. *Am J Gastroenterol* 2006; 101: 2833-2840.
58. Corbetta S, Bulfamante G, Cortelazzi D, **Barresi V**, Cetin I, Mantovani G, Bondioni S, Beck-Peccoz P, Spada A. Adiponectin expression in human fetal tissues during mid- and late gestation. *J Clin Endocrinol Metab*. 2005 Apr;90(4):2397-402.
59. Trovato M, Grosso M, Vitarelli E, Le Donne M, **Barresi V**, Trimarchi F, Barresi G. Immunoexpression of CD30 and CD30 ligand in deciduas from spontaneous abortions. *Eur J Histochem*. 2005 Jul-Sep;49(3):285-90.
60. Bankfalvi A, Giuffrè G, Ofner D, Diallo R, Poremba C, Buchwalow IB, **Barresi V**, Bocker W, Tuccari G. Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysis. *Int J Oncol*. 2003 Nov;23(5):1285-92.

Verona, March the 10th 2024

Prof. Valeria Barresi

